Market Overview

UPDATE: Dawson James Reiterates Agenus Inc. at Buy After Rapid Phase II Trial Enrollment on HerbV

Share:
Related AGEN
18 Biggest Mid-Day Gainers For Tuesday
Agenus Gets A Boost From Incyte Cash Infusion

In a report published by Dawson James, analyst Robert M. Wasserman reiterated a Buy rating and $6.00 price target on Agenus, Inc. (NASDAQ: AGEN)

Dawson James reported that, “Key developments for the fourth quarter for Agenus included the November publication of the second complete results from the Phase 3 trial of GSK's malaria vaccine candidate and the start of a Phase 2 multicenter study of HerpV for the treatment of genital herpes in HSV-2 positive subjects. Subsequent to year-end, Agenus completed enrollment in this Phase 2 HerpV viral shedding study, with results expected to be released by the end of this year.”

Shares of Agenus, Inc. closed at $4.46 on Monday.

Latest Ratings for AGEN

DateFirmActionFromTo
Oct 2016H.C. WainwrightDowngradesBuyNeutral
Jul 2016JefferiesMaintainsBuy
Mar 2016Maxim GroupUpgradesHoldBuy

View More Analyst Ratings for AGEN
View the Latest Analyst Ratings

Posted-In: Dawson JamesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (AGEN)

View Comments and Join the Discussion!